https://www.selleckchem.com/products/super-tdu.html It is worldwide recognized that the use of pharmaceuticals for human and veterinary purposes could lead to unsustainable effects on the environment. A strategy to reduce the impact of pharmaceuticals on the environment has been recently established at European level, where guidelines to evaluate the impacts of veterinary drugs used to treat animal diseases are in place. The aim of this article is to focus on the worldwide used antiparasitic drug ivermectin (IVM) and its potential impact on the environment. A specific section is related to the IVM resistance that the massive use of this drug could generate enhancing the risk scenarios also for human health. The application of stringent measures for the veterinary use of this substance, in line with the recommendations provided by International frameworks such as One Health and EcoHealth, is recommended.The results obtained with basic research showing significant therapeutic promise are often not translated into clinical applications. The purpose of translational research is to favour the transition of basic research to application at the patient's bedside, and from here to routine clinical practice (without excluding the opposite pathway, in which the evidence generated by clinical practice helps to guide research). Although translational research can provide patients with valuable therapeutic resources, it is not risk-free. The most significant ethical issues in translational research on medicinal products derive from the risk of the intention to shorten the timeframes for the application of the results of the research making the scientific methods adopted and the regulatory requisites to be satisfied along the long path from the bench to the patient's bedside less rigorous. This is also relevant during pandemics when shortening the timeline from basic research to bedside is even more crucial. It is therefore necessary to establish defined and agreed requisites in